Evidence map›Paper›PMID 33772754›Full record

ReviewClinical and experimental immunology2021

Endothelial-to-mesenchymal transition in systemic sclerosis.

P Di Benedetto, P Ruscitti, O Berardicurti, M Vomero, L Navarini, V Dolo, P Cipriani, R Giacomelli

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Clinical and experimental immunology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 36 papers.

0numbers the graph read from it
0cells of the map it votes in
36citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

36 citing papers in PubMed.

  1. Trial
  2. Trial
  3. Review
  4. Article
  5. [Nan fang yi ke da xue xue bao = Journal of Southern Medical University · 2026
    Article
  6. Article
  7. Review
  8. Review
  9. Review
  10. Review
  11. Review
  12. Review
  13. Article
  14. Article
  15. Review
  16. Article
  17. Review
  18. Review
  19. Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

P Di BenedettoClinical Pathology Unit, Department of Biotechnological and Applied Clinical Sciences, University of L'Aquila, L'Aquila, Italy.
P RuscittiDivision of Rheumatology, Department of Biotechnological and Applied Clinical Sciences, University of L'Aquila, L'Aquila, Italy.
O BerardicurtiDivision of Rheumatology, Department of Biotechnological and Applied Clinical Sciences, University of L'Aquila, L'Aquila, Italy.
M VomeroUnit of Rheumatology and Clinical Immunology, University of Rome 'Campus Biomedico', Rome, Italy.
L NavariniUnit of Rheumatology and Clinical Immunology, University of Rome 'Campus Biomedico', Rome, Italy.
V DoloClinical Pathology Unit, Department of Life, Health and Environmental Sciences, University of L'Aquila, L'Aquila, Italy.
P Cipriani *Division of Rheumatology, Department of Biotechnological and Applied Clinical Sciences, University of L'Aquila, L'Aquila, Italy.
R Giacomelli *Unit of Rheumatology and Clinical Immunology, University of Rome 'Campus Biomedico', Rome, Italy.ORCID 0000-0003-0670-9638

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Systemic sclerosis (SSc) is an autoimmune disease characterized by significant vascular alterations and multi-organ fibrosis. Microvascular alterations are the first event of SSc and injured endothelial cells (ECs) may transdifferentiate towards myofibroblasts, the cells responsible for fibrosis and collagen deposition. This process is identified as endothelial-to-mesenchymal transition (EndMT), and understanding of its development is pivotal to identify early pathogenetic events and new therapeutic targets for SSc. In this review, we have highlighted the molecular mechanisms of EndMT and summarize the evidence of the role played by EndMT during the development of progressive fibrosis in SSc, also exploring the possible therapeutic role of its inhibition.

Indexed as

AnimalsEndothelial CellsEndotheliumEpithelial-Mesenchymal TransitionFibrosisHumansMyofibroblastsScleroderma, Systemicendothelial cellsendothelial-to-mesenchymal transitionsystemic sclerosis

Identifiers

PMID33772754
PMCPMC8209570

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.